Pharmacokinetics and safety of panobacumab : specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.

Qin Lu,Jean-Jacques Rouby,Pierre-François Laterre,Philippe Eggimann,Anthony Dugard,Evangelos J. Giamarellos-Bourboulis,Emanuelle Mercier,Jorge Garbino,Charles-Edouard Luyt,Jean Chastre,Violetta Georgescu-Kyburz,Michael P. Rudolf,Verena Gafner,Hedvika Lazar,Holger Koch,Antonio Pérez,Stefanie D. Krämer,Michael Tamm

Pharmacokinetics and safety of panobacumab : specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.

2011

Qin Lu
Jean-Jacques Rouby
Pierre-François Laterre
Philippe Eggimann
Anthony Dugard
Evangelos J. Giamarellos-Bourboulis
Emanuelle Mercier
Jorge Garbino
Charles-Edouard Luyt
Jean Chastre
Violetta Georgescu-Kyburz
Michael P. Rudolf
Verena Gafner
Hedvika Lazar
Holger Koch
Antonio Pérez
Stefanie D. Krämer
Michael Tamm

Nosocomial Pseudomonas aeruginosa pneumonia remains a major concern in critically ill patients. We explored the potential impact of microorganism-targeted adjunctive immunotherapy in such patients.

Keywords:

Serum drug concentration
Respiratory disease
Ventilator-associated pneumonia
Immunotherapy
Panobacumab
Intensive care medicine
Survival rate
Medicine
Pharmacokinetics
Pseudomonas aeruginosa
critically ill

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations